Clindamycin vaginal gel is a prescription medicine distinct from both clindamycin acne gel and clindamycin vaginal cream. In the U.S. product family covered here, Xaciato is a labeled 2% clindamycin phosphate vaginal gel for bacterial vaginosis. Its presentation is a tube used to fill a single applicator, with product-specific directions and precautions.
The phrase “2% clindamycin gel” does not by itself identify the right product. Xaciato is a vaginal gel, whereas clindamycin gel for acne is applied to skin and is commonly labeled 1%. Vaginal cream and ovules also have different vehicles and applicator systems. The broader vaginal clindamycin overview can help locate the correct family.
This page focuses on the gel form and Xaciato labeling, including the kit, prescription matching, warnings and pharmacy questions. It does not imply that an unbranded generic vaginal gel is routinely available or that any online seller has stock. For a product-entity deep dive use Xaciato; for the clinical diagnosis see clindamycin for BV.
Xaciato contains clindamycin phosphate vaginal gel at 2% and is labeled for BV in patients within the age group described in its U.S. prescribing information. This dosage form is explicitly for intravaginal use, not oral, eye or skin use. Matching the form and brand identity matters when a pharmacy website has several clindamycin results.
For this gel presentation, a patient should check the complete product name, 2% concentration, applicator and package description. The term “clindamycin gel” without a route qualifier is ambiguous and can lead to an acne medicine result rather than the intended vaginal product.
| Label detail | Xaciato vaginal gel | Why to check |
|---|---|---|
| Route | Vaginal | Not acne skin gel |
| Strength | 2% clindamycin | Distinct from 1% topical |
| Tube | 8 g package | Verify dispensed kit |
| Applicator | Single user-filled device | Not prefilled Clindesse |
| Administration | Single labeled application | Follow exact prescription |
| Barrier precaution | Polyurethane condom warning | Product-specific seven-day period |
Xaciato labeling describes an 8 g tube of vaginal gel and a single disposable applicator that the patient fills. The applicator delivers 5 g of gel containing 100 mg clindamycin in the labeled single administration. The distinction between tube content and applicator delivery is important for understanding package descriptions.
This is not the same hardware as a prefilled Clindesse cream applicator. The person dispensing the prescription should provide the original patient instructions and explain how to identify a complete package. A kit with missing components or a mismatched label should be reviewed with the pharmacy before use.
Clindamycin skin gels commonly have 1% labeling for acne vulgaris, while Xaciato uses a 2% vaginal formulation for BV. The route, vehicle, indication and packaging are different. Applying one to the other site can expose tissue to the wrong ingredients and bypass the specific prescribing information.
The topical acne gel guide describes a separate U.S. medicine family. Do not accept a substitution based on the words “clindamycin” and “gel” alone, and do not assume a pharmacy image is accurate without checking the actual package.
Xaciato gel is neither a standard multidose vaginal cream nor a single-dose Clindesse cream. Cream preparations can have oil-based vehicles that carry latex-barrier warnings. Xaciato has its own formulation, user-filled applicator and a distinct barrier warning centered on polyurethane condoms.
See vaginal cream 2% for cream presentations and Clindesse for the prefilled single-dose cream. Patients should not infer relative effectiveness or choose among these forms solely by comparing a percentage on their cartons.
The Xaciato U.S. label warns that polyurethane condoms may be weakened during its use and for seven days afterward, potentially making them unreliable for pregnancy or infection prevention. The label directs use of latex or polyisoprene condoms rather than polyurethane condoms during this period.
Because this differs from the oil-based vaginal cream and ovule cautions, do not transfer contraceptive advice between formulations. Ask a clinician or pharmacist how the product-specific warning relates to the patient’s contraception and STI-prevention needs.
Xaciato labeling includes possible vulvovaginal discomfort and yeast infection, and warnings about clindamycin-associated diarrhea or colitis. Lower systemic exposure through the vaginal route does not mean the medicine is risk-free. Severe diarrhea, major abdominal symptoms or allergic reactions require medical evaluation.
If new vaginal symptoms persist or worsen, a clinician should reconsider the diagnosis rather than assuming another applicator is needed. The product is not a general vaginal-care gel or a nonprescription treatment for any discharge.
BV may resemble other causes of vaginal discharge, odor and irritation. A clinician can determine whether symptoms and findings support BV and whether this specific labeled medicine is an appropriate option. That decision may take pregnancy, other conditions and prior treatment into account.
The CDC discusses a number of recommended and alternative BV regimens, which do not all use the same route or treatment schedule. For an indication-level discussion rather than a gel product description, see clindamycin for bacterial vaginosis.
A branded prescription product may appear in drug-label databases, but the existence of a current label alone cannot establish that a particular pharmacy can supply it. Do not treat an unrelated generic skin gel as a generic substitute for Xaciato. The pharmacist should identify an authorized product and confirm actual availability.
If a pharmacy cannot locate the prescribed gel, ask about contacting the prescriber. Any change from gel to cream, ovules or an oral drug should be evaluated rather than improvised at checkout.
Confirm the labeled route, strength, single-dose product identity, tube, applicator, expiry and instructions in the supplied leaflet. Ask the pharmacist to explain the specific protection warning and whether other vaginal products should be avoided during treatment.
Retain the package instructions while the product is in use. Report a missing applicator, damaged tube, unclear prescription or unexpected product to the pharmacy rather than attempting to adapt a skin-gel applicator or another vaginal device.
Xaciato clindamycin phosphate vaginal gel 2% is a prescription vaginal product, not an over-the-counter skin treatment. A pharmacy needs to match the name or authorized generic, exact vaginal form, concentration, applicator configuration and prescriber instructions. The distinction between a cream, gel and ovule is clinically meaningful even when the product name contains clindamycin. See U.S. prescription requirements for the legal access framework.
The Xaciato label describes an 8 g tube supplied with a single user-filled applicator delivering 5 g of 2% vaginal gel; verify the full kit rather than searching for generic acne gel. If a pharmacy proposes a different formulation, ask the dispensing pharmacist to contact the prescriber when needed. Consumers should not translate the percentage on one package into an unsupervised dose of another form. The availability verification guide explains how to inquire about a precise product without assuming any pharmacy has current stock.
Xaciato labeling specifically warns that polyurethane condoms may be weakened during treatment and for seven days after use; its label says latex or polyisoprene condoms should be used instead during that period. This differs from oil-based cream and ovule warnings. Patients should follow the particular package instructions for intercourse, other vaginal products and barrier contraception. These restrictions differ among cream, gel and ovule formulations; advice borrowed from a different clindamycin product can be wrong.
With Xaciato clindamycin phosphate vaginal gel 2%, local administration does not eliminate the risk of antibiotic-associated diarrhea, including potentially serious C. difficile-associated illness. Severe or persistent diarrhea, bloody stools, marked abdominal pain or serious allergic symptoms warrant prompt clinical assessment. New fever, pelvic pain, bleeding or symptoms that do not fit a previously confirmed diagnosis should be assessed rather than repeatedly self-treated.
This branded vaginal gel presentation has its own coverage and package considerations; a cost quote for a skin gel or vaginal cream does not describe the same product. Payment varies with the precise brand or generic, applicator package, available supply, formulary coverage and whether the pharmacy can dispense the prescribed presentation. Product cost should never be estimated from a similarly named skin gel or oral capsule; the label and route must match.
Before accepting Xaciato clindamycin phosphate vaginal gel 2%, confirm the vaginal route, concentration, form, number of applicators or units, expiration, storage instructions and any contraceptive-barrier warning. For ways to evaluate payment without unreliable live price quotes, use vaginal clindamycin cost factors.
Yes. Xaciato is a prescription clindamycin phosphate 2% vaginal gel labeled for bacterial vaginosis.
No. Xaciato is formulated for vaginal use, whereas clindamycin acne gel is a different topical skin product.
No. The labeled kit contains a tube and a user-filled single-dose applicator.
Do not infer generic availability from other clindamycin gel listings. Ask a pharmacist to identify any legitimate alternative.
Its label specifically warns about polyurethane condoms during treatment and for seven days afterward; follow the product’s detailed instructions.
The Xaciato label directs using latex or polyisoprene condoms rather than polyurethane during the specified period.
No. It is a vaginal prescription gel, not a skin acne treatment.
Vulvovaginal candidiasis is a labeled adverse reaction. Ask a clinician about new or troublesome symptoms.
Check the Xaciato name, 2% vaginal route, complete tube-and-applicator kit, prescription directions and barrier precautions.